NCT01101581 2021-08-18
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Gilead Sciences
Phase 1/2 Withdrawn
Clinical Trials
1 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma × veltuzumab × Other hematologic neoplasm × Clear all